Quantcast

OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific

May 12, 2009

OMNICOMM CONTINUES ITS EXPANSION INTO EUROPE AND STRENGTHENS ITS SENIOR MANAGEMENT TEAM

FT. LAUDERDALE, Fla., May 12 /PRNewswire-FirstCall/ — OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that it has strengthened its European presence and management team with the addition of Dr. Wolfgang Summa. As Executive Vice President, Europe & Asia/Pacific based in OmniComm’s Bonn, Germany facility, Dr. Summa will be focused on the expansion of our products and services throughout Europe and the Asia Pacific area.

“OmniComm is well positioned to offer leading edge products and services to the international community,” said Cornelis F. Wit, CEO of OmniComm. “We have expanded our client services in Europe to include help desk support in eight languages and added clinical and professional services expertise, along with additional project management, quality assurance, development and sales and marketing. Dr. Summa will be a strong addition to an already seasoned team in Europe.”

Dr. Summa comes to OmniComm most recently from invivodata, where he spent 2 years as Vice President Europe & Asia Pacific, leading the European operational and business development team and driving the expansion of patient diary solutions in the European and Asian markets. Prior to invivodata, Dr. Summa held positions ranging from Vice President Global Operations to Vice President Enterprise Consulting and Managing Director Europe at DATATRAK International. Dr. Summa also serves as member of the European Coordinating Committee of CDISC (Clinical Data Interchange Standards Consortium). Dr. Summa has 14 years of experience in the pharmaceutical industry with a strong focus on EDC and new technologies.

“I am excited about joining the OmniComm team,” said Dr. Summa. “The unique combination of product vision and outstanding customer service makes this company the ideal partner for global customers. Working with an excellent team of experienced EDC executives makes this a great place to work.”

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm’s growing base of satisfied customers is a direct result of the company’s commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm’s client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Chicago, Germany, Tula, Russia, California, New York, North Carolina, Tennessee, Massachusetts and Georgia.

Safe Harbor Disclaimer

Statements about OmniComm’s future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm’s operations, markets and profitability, actual results could differ materially and adversely from the expected results.

SOURCE OmniComm Systems, Inc.


Source: newswire



comments powered by Disqus